Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported a tax-related share disposition. On the vesting of a restricted stock unit (RSU) award, 22,505 shares of Class A Common Stock were withheld at $0.7291 per share to satisfy tax obligations. This was not an open-market sale, but an automatic tax-withholding mechanism. After this RSU-related withholding, Locklear directly held 443,181 shares, which include RSUs that are still subject to future vesting.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a tax-related share disposition. On this Form 4, 22,505 shares of Class A Common Stock were withheld at $0.7291 per share to cover tax obligations tied to the vesting of a restricted stock unit award. After this tax-withholding event, she holds 430,914 shares directly, which includes restricted stock units that remain subject to future vesting.
Longeveron Inc. executive Devin Blass, CTO & SVP of CMC, reported a routine tax-withholding disposition related to equity compensation. On the reported date, 15,808 shares of Class A Common Stock were withheld at $0.7291 per share to satisfy tax obligations from vesting restricted stock units. Following this non-market transaction, Blass holds 425,735 shares directly, which the footnotes state include RSUs subject to future vesting.
Longeveron Inc. General Counsel and Secretary Paul T. Lehr reported a routine tax-related share disposition. On July 1, 2026, 13,143 shares of Class A Common Stock were withheld at an effective price of $0.7291 per share to satisfy tax obligations from the vesting of a restricted stock unit (RSU) award. This was an automatic tax-withholding event, not an open-market sale.
After this transaction, Lehr directly held 575,423 shares of Longeveron Class A Common Stock, which the filing notes includes RSUs that are still subject to future vesting. The filing shows no option exercises or open-market purchases or sales by Lehr in this report.
Longeveron Inc. announced leadership and capital structure changes. The company appointed Marie Washburn as Senior Vice President and Chief Financial Officer, principal financial officer and principal accounting officer, effective July 13, 2026, succeeding Lisa Locklear. Her package includes a $340,000 base salary, a target annual cash incentive equal to 45% of salary, and an initial grant of 130,000 time-based restricted stock units.
The Board also appointed Dr. Arjun “JJ” Desai as a Class III director to fill a current vacancy. At the July 1, 2026 annual meeting, stockholders approved an amendment to the charter increasing authorized Class A common stock to 175,000,000 shares, authorized a reverse stock split in a range of 1:2 to 1:20 at the Board’s discretion, and increased the 2021 Incentive Award Plan share pool by 5,000,000 shares. Stockholders also re-elected three directors and ratified the 2026 independent auditor.
Longeveron Inc. announced a planned leadership change in its finance team. On June 1, 2026, Chief Financial Officer Lisa Locklear informed management she will step down from the CFO role effective July 10, 2026. She plans to pursue board opportunities and other professional and personal interests, and the company states her resignation is not due to any disagreement over operations, policies, or practices.
Longeveron expects its current controller, Marie Washburn, to be elevated into the CFO position following Locklear’s departure, pending finalization of her contract. This indicates an internal succession approach rather than an external search.
Longeveron Inc. is asking stockholders to approve several major corporate actions at a fully virtual annual meeting on July 1, 2026. Proposals include electing three Class II directors, sharply increasing authorized Class A common shares to 175,000,000, and authorizing a reverse stock split between 1:2 and 1:20 to support Nasdaq listing requirements.
The company also seeks to add 5,000,000 shares to its 2021 Incentive Award Plan, bringing the plan total to 10,657,440 shares, and to ratify CBIZ CPAs P.C. as auditor for fiscal 2026. As of the May 11, 2026 record date, there were 30,148,947 Class A and 1,449,005 Class B shares outstanding, with Class B carrying five votes per share.
Longeveron Inc. ownership reported by Janus Henderson Group plc: 1,291,331 shares, representing 5.9% of Class A Common Stock as of 03/31/2026.
The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of multiple managed portfolios and disclaim rights to dividends or sale proceeds tied to those portfolio clients.
Longeveron Inc. reported first quarter 2026 results and outlined a shift to a more capital-efficient, asset-light model focused on partnering its stem cell therapy laromestrocel across four programs. For the quarter ended March 31, 2026, revenue was $398,000, slightly above $381,000 a year earlier, driven mainly by clinical trial revenue.
The company posted a net loss of $4.7 million, modestly improved from a $5.0 million loss in 2025, with operating expenses of $5.0 million. Basic and diluted net loss per share was $0.19 on 24.8 million weighted average shares. Cash and cash equivalents rose to $15.8 million from $4.7 million at December 31, 2025, increasing total assets to $21.2 million.
Longeveron highlighted upcoming catalysts, including top-line Phase 2b results in Hypoplastic Left Heart Syndrome expected in August 2026, and described an active partnering strategy targeting HLHS, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.